Suven Life Sciences Limited has announced that the United States Food and Drug Administration (US FDA) has given a nod to its Investigational New Drug (IND) application for SUVN-I6107, granting a “Study may proceed” letter to start a first-in-human Phase 1 clinical trial. SUVN-I6107 is a novel muscarinic M1 receptor-positive allosteric modulator, which represents a …